rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
Dan LiTianyuzhou LiangLaura E HutchinsAlexandra A WolfarthSara Ferrando-MartinezByung Ha LeeMitchell HoPublished in: Journal for immunotherapy of cancer (2024)
This study provides a rationale for NT-I7 plus CAR-T cell combination therapy for solid tumors in humans.
Keyphrases